Entereg is a brand name of alvimopan, approved by the FDA in the following formulation(s):
ENTEREG (alvimopan - capsule; oral)
Manufacturer: ADOLOR
Approval date: May 20, 2008
Strength(s): 12MG [RLD]
Has a generic version of Entereg been approved?
No. There is currently no therapeutically equivalent version of Entereg available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Entereg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Peripherally selective piperidine carboxylate opioid antagonists
Patent 5,250,542
Issued: October 5, 1993
Inventor(s): Cantrell; Buddy E. & Zimmerman; Dennis M.
Assignee(s): Eli Lilly and Company
3,4,4-trisubstitutedpiperidinyl-N-alkylcarboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.Patent expiration dates:
- March 29, 2016✓✓✓
- March 29, 2016
Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
Patent 5,434,171
Issued: July 18, 1995
Inventor(s): Frank; Scott A. & Prather; Douglas E. & Ward; Jeffrey A. & Werner; John A.
Assignee(s): Eli Lilly and Company
This invention relates to a process for preparing certain 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates, intermediates, and congeners. Finally, the invention provides new 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates with formulations and methods for using the compounds.Patent expiration dates:
- December 8, 2013✓✓✓
- December 8, 2013
Methods for the treatment and prevention of ileus
Patent 6,469,030
Issued: October 22, 2002
Inventor(s): John J.; Farrar & Peter J.; Schied & William K.; Schmidt & Randall L.; Carpenter
Assignee(s): Adolor Corporation
Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.Patent expiration dates:
- November 29, 2020✓
- November 29, 2020
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- May 20, 2013 - NEW CHEMICAL ENTITY
See also...
- Entereg Consumer Information (Drugs.com)
- Entereg Consumer Information (Wolters Kluwer)
- Entereg Consumer Information (Cerner Multum)
- Entereg Advanced Consumer Information (Micromedex)
- Entereg AHFS DI Monographs (ASHP)
- Alvimopan Consumer Information (Wolters Kluwer)
- Alvimopan Consumer Information (Cerner Multum)
- Alvimopan Advanced Consumer Information (Micromedex)
- Alvimopan AHFS DI Monographs (ASHP)
